Sökning: "Klinisk läkemedelsutveckling"

Visar resultat 1 - 5 av 6 avhandlingar innehållade orden Klinisk läkemedelsutveckling.

  1. 1. Preclinical and Clinical Development of the Novel Cyanoguanidine CHS 828 for Cancer Treatment

    Författare :Peter Hovstadius; Rolf Larsson; Elin Lindhagen; Martin Höglund; Sigurd Vitols; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Clinical drug development; CHS 828; Cyanoguanidines; Oncology; Clinical Drug Development; Klinisk läkemedelsutveckling; Pharmaceutical chemistry; Läkemedelskemi;

    Sammanfattning : CHS 828 is a cyanoguanidine with anti-tumour properties which has shown promising effects in several preclinical models. This thesis describes both preclinical and clinical studies aiming to investigate disease specific activity, clinical tolerability and efficacy of CHS 828. LÄS MER

  3. 2. On Cholecystokinin and Phospholipase A2 in Insulin Secretion - an Experimental Study With Reference to the Development of Diabetes

    Författare :Erik Simonsson; Malmö Institutionen för kliniska vetenskaper; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Type 2 Diabetes; Insulin Resistance; Islet; Beta-cell; Insulin Secretion; Ca2 -Dependency; Intracellular Signalling; Phospholipase A2; Cholecystokinin; Non-glucose Secretagogues; Endocrinology; secreting systems; diabetology; Endokrinologi; sekretion; diabetologi;

    Sammanfattning : In view of unsolved issues regarding cellular events underlying the adaptation of insulin secretion to insulin resistance, together with the observation that insulin secretion induced by the gastrointestinal hormone and neuropeptide cholecystokinin (CCK) is not solely explained by phospholipase C-protein kinase C (PLC-PKC) pathway activation, this study aimed at delineate mechanisms responsible for the hyperinsulinemia in insulin resistance, with particular attention paid to the action of glucose vs. non-glucose secretagogues, such as CCK. LÄS MER

  4. 3. Application of In Vitro Chemosensitivity Testing for Evaluation of New Cytotoxic Drugs in Chronic Lymphocytic Leukaemia

    Författare :Anna Åleskog; Jan Liliemark; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Clinical drug development; chronic lymphocytic leukaemia; cytotoxicity; in vitro assay; cytotoxic drug development; CHS 828; IgVH mutation status; Klinisk läkemedelsutveckling; Pharmaceutical chemistry; Läkemedelskemi; Clinical Pharmacology; klinisk farmakologi;

    Sammanfattning : Despite major advances in the understanding of the biology of chronic lymphocytic leukaemia (CLL), progress in improving its treatment has been limited and it still remains an incurable disorder. In the present research, we have performed in vitro drug sensitivity testing of primary CLL cells for preclinical evaluation of cytotoxic drugs, using the fluorometric microculture cytotoxicity assay (FMCA). LÄS MER

  5. 4. Change in the Pharmaceutical Industry : Aspects on Innovation, Entrepreneurship, Openness, and Decision Making

    Författare :Thomas Hedner; Magnus Klofsten; Johan Braet; Mirjam Knockaert; Linköpings universitet; []
    Nyckelord :Pharmaceutical industry; Big Pharma; life sciences; drug discovery; drug development; R D; business model; innovation; closed innovation; open innovation; entrepreneurship; intellectual property; multiple stakeholders; decision making; judgment; uncertainty; go no-go; go no-go recycle; company; SME.; Läkemedelsindustri; Big Pharma; biovetenskap; läkemedelsutveckling; utveckling av läkemedel; FoU; affärsmodell; innovation; stängd innovation; öppen innovation; entreprenörskap; immaterialrätt; beslutsfattande; osäkerhet; go no-go; go no-go recycle; företag; små och medelstora företag;

    Sammanfattning : Over the past century, the pharmaceutical industry has been a major contributor of individual and population health and societal wealth. Its products and services have contributed to longevity of large groups of patients and symptom relief from major diseases. LÄS MER

  7. 5. VENOUS THROMBOEMBOLISM IN SOUTHERN SWEDEN EPIDEMIOLOGY AND RISK FACTORS

    Författare :Nazim Isma; Vaskulära sjukdomar - kliniska studier; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; epidemiology; Venous thromboembolism VTE ; risk factors; factor V leiden FVL ; socioeconomic status SES ; upper extremety deep venous thrombosis UEDVT ; haemoglobin Hb ; low molecular weight heparin LMWH ; labour;

    Sammanfattning : Despite the fact that venous thromboembolism (VTE) is an important cause of morbidity and mortality there is still insufficient information on VTE risk factors and patient characteristics in the general population. Previously published incidences of VTE (deep venous thrombosis [DVT] and pulmonary embolism [PE]) vary from 71 to 192 per 100,000 individuals per year. LÄS MER